Press Release

Feb, 02 2024

Understanding Optic Neuritis: Causes, Symptoms, Diagnosis, Treatment, and Impact on Vision and Health

Optic neuritis is an inflammation of the optic nerve, disrupting communication between the eye and brain. Commonly associated with autoimmune disorders such as multiple sclerosis, it can also result from infections or idiopathic causes. Symptoms include vision loss, blurred vision, pain with eye movement, and color perception issues. Diagnosis involves eye examinations and imaging tests. Treatment often includes corticosteroids to reduce inflammation. While most cases resolve with time, optic neuritis may leave residual visual impairment. Regular follow-up with healthcare professionals is crucial for managing the condition and addressing underlying causes, ensuring optimal vision and overall well-being.

Access Full Report @

Data Bridge Market Research analyses that the U.S. Optic Neuritis Market, which was USD 4.15 million in 2021, is expected to reach USD 6.11 million by 2029 and is expected to undergo a CAGR of 5.0% during the forecast period from 2022 to 2029. A growing aging demographic propels the increasing prevalence of optic neuritis. As the population ages, the incidence of this condition rises, expanding the patient pool and stimulating market growth.

Key Findings of the Study

U.S. Optic Neuritis Market

Patient-centric approaches are expected to drive the market's growth rate

Patient-centric approaches in the optic neuritis market prioritize tailoring treatments to meet individual patient needs and preferences. This emphasis on personalized care enhances the development of more patient-friendly therapies, fostering increased demand in the market. The industry addresses medical aspects by aligning treatments with patient expectations and comfort. It promotes a holistic and positive patient experience, ultimately contributing to the growth and success of optic neuritis-related products and services.

Report Scope and Market Segmentation

Report Metric


Forecast Period

2022 to 2029

Base Year


Historic Years

2020 (Customizable to 2014-2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Treatment (Corticosteroids, IV Immunoglobulin, Supplements, and Others), Diagnosis (MRI Scan, Lumbar Puncture, Ocular Coherence Tomography, Blood Test, and Others), Route of Administration (Parenteral, and Oral), End User (Hospitals, Clinics, Academics and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others)

Market Players Covered

AbbVie Inc. (U.S.), Bausch & Lomb Incorporated (U.S.), Boehringer Ingelheim International GmbH (Germany), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Hikma Pharmaceuticals PLC (Jordan), Fresenius Kabi USA (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), GSK plc (GlaxoSmithKline) (U.K.), Pfizer (U.S.), Akorn Operating Company LLC U(U.S.), AdvaCare Pharma (U.S.), Bristol-Myers Squibb Company (U.S.), Jubilant Cadista Pharmaceuticals Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Viatris Inc. (U.S.), Novitium Pharma (U.S.), Accure Therapeutics (U.S.), Noveome Biotherapeutics, Inc. (U.S.), Biogen (U.S.), Mallinckrodt (U.K.), Acorda Therapeutics (U.S.), Sanofi (France) among others            

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The U.S. optic neuritis market is segmented on the basis of treatment, diagnosis, route of administration, end user, and distribution channel.

  • On the basis of treatment, the U.S. optic neuritis market is segmented into corticosteroids, IV Immunoglobulin, Supplements, and Others
  • On the basis of diagnosis, the U.S. optic neuritis market is segmented into MRI scans, lumbar puncture, ocular coherence tomography, blood test, and others
  • On the basis of route of administration, the U.S. optic neuritis market is segmented into parenteral, and oral
  • On the basis of end user, the U.S. optic neuritis market is segmented into hospitals, clinics, academic and research institutes, and others
  • On the basis of distribution channel, the U.S. optic neuritis market is segmented into hospital pharmacy, retail pharmacy, and others

Major Players

Data Bridge Market Research recognizes the following companies as the major U.S. optic neuritis market players in U.S. optic neuritis market are AbbVie Inc. (U.S.), Bausch & Lomb Incorporated (U.S.), Boehringer Ingelheim International GmbH (Germany), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Hikma Pharmaceuticals PLC (Jordan)

U.S. Optic Neuritis Market

Market Developments

  • In October 2022, Trethera secured a notable USD 1.6 million grant to advance the development of TRE-515 as a potential therapy for optic neuritis, a prevalent symptom in multiple sclerosis (MS). This funding underscores the commitment to exploring innovative solutions for optic neuritis, offering hope for enhanced treatments and improved outcomes, especially in the context of MS-related complications
  • In August 2022, the U.S. FDA awarded orphan drug status to Trethera Corporation's oral therapy, TRE-515, designed for demyelinating optic neuritis. This experimental treatment holds promise for addressing optic neuritis, which can potentially advance to multiple sclerosis or manifest during its progression. The orphan drug designation recognizes TRE-515's potential to fulfill unmet medical needs in managing this vision-threatening condition
  • In June 2022, Boehringer Ingelheim GmbH secured an acquisition option for Trutino Biosciences Inc., a San Diego-based biotech firm specializing in pre-clinical stage research for diverse disease treatments. This strategic move enhances Boehringer Ingelheim's global footprint and broadens its product offerings, positioning the company for growth and innovation in the competitive biopharmaceutical market
  • In September 2021, Novartis AG acquired Arctos Medical to broaden its optogenetics portfolio, aiming to advance gene therapies for individuals with profound vision impairment. This strategic move underscores Novartis's dedication to pioneering treatments and commitment to therapeutic success. The acquisition reinforces the company's position in developing innovative solutions for severe vision loss, aligning with its mission to enhance patient outcomes through cutting-edge therapeutic approaches

For more detailed information about the U.S. optic neuritis market report, click here –

Client Testimonials